Anthropic acquires Coefficient Bio for $400M, deepening its push into drug discovery and life sciences

Anthropic Acquires Eight-Month-Old Stealth Biotech AI Startup

Anthropic has completed the acquisition of Coefficient Bio, a stealth biotech AI startup founded barely eight months ago, in an all-stock deal valued at just over $400 million 1

1

2

2

. The deal brings a team of fewer than 10 people into Anthropic's healthcare and life sciences division, nearly all of whom are former Genentech computational biology researchers 2

2

. Sources close to the deal confirmed to TechCrunch that it closed, though they declined to comment on the specific amount 1

1

.

Coefficient Bio's co-founders, Samuel Stanton and Nathan C. Frey, launched the startup after both working in computational drug discovery at Genentech's Prescient Design unit 1

1

. Frey led a multidisciplinary group at Prescient Design working on biological foundation models and novel machine learning approaches to biomolecule design, with a publication record spanning more than 20 papers in journals including Science Advances and Nature Machine Intelligence 2

2

. He won an ICLR Outstanding Paper Award in 2024 for work on generative modeling for drug candidate discovery 2

2

.

AI Models for Biology and Drug Discovery Ambitions

The $400 million acquisition values a company with no publicly known product, no disclosed revenue, and no conventional traction metrics 2

2

. What Coefficient Bio did have was rare expertise and an ambitious vision: artificial superintelligence for science 2

2

. The startup had built a platform enabling AI to draft drug research and development plans, manage clinical regulatory strategy, and identify new drug candidates 3

3

5

5

. In a January post on X, co-founder Stanton stated the company was "ushering biopharma into the Intelligence Age" and that it would "change everything about how the industry learns and makes decisions" 3

3

4

4

.

Dimension, the New York-based venture capital firm founded in 2023 by former Lux Capital and Obvious Ventures partners, held roughly half of Coefficient Bio and is now reporting a 38,513 percent internal rate of return on the investment 2

2

. Against Anthropic's $380 billion post-money valuation, set in its $30 billion Series G round in February, the acquisition represents roughly 0.1 percent dilution 2

2

.

Deepening Claude for Life Sciences Strategy

The deal comes as Anthropic continues its push into healthcare and life sciences, following its October announcement of Claude for Life Sciences, a tool designed to help scientific researchers make discoveries 1

1

. The Coefficient Bio team will join Anthropic's Health Care Life Sciences group, led by Eric Kauderer-Abrams, who was hired in 2025 with an explicit mandate to make Claude the dominant AI model in biology 2

2

. "We want a meaningful percentage of all of the life science work in the world to run on Claude, in the same way that that happens today with coding," Kauderer-Abrams told CNBC when Anthropic launched Claude for Life Sciences in October 2025 2

2

.

That platform integrates with tools including Benchling, PubMed, and 10x Genomics, and was designed to assist researchers across the entire drug discovery pipeline, from literature review and hypothesis generation to data analysis and regulatory submissions 2

2

5

5

. Where Claude for Life Sciences offered a generalized research assistant, Coefficient Bio's team brings domain-specific expertise in protein design and biomolecule modeling that could help Anthropic build specialized tools for pharmaceutical companies willing to pay enterprise AI prices for AI that understands their workflows at a molecular level 2

2

.

Competing in the AI-Biopharma Sector

Anthropic is not entering a vacuum. Google DeepMind spun off Isomorphic Labs to pursue AI-designed drug candidates now entering clinical trials, and Nvidia announced a five-year, $1 billion partnership with Eli Lilly in January to build an AI co-innovation lab for accelerated drug discovery 2

2

. OpenAI, meanwhile, has been working with Moderna to speed the development of personalized cancer vaccines 2

2

. The competitive logic is straightforward: whichever foundation model becomes embedded in biopharma R&D workflows will capture an enormous and recurring revenue stream in a market where a single approved drug can generate billions 2

2

.

AI can speed up small molecule discovery, one of the most important medical research workflows, by a factor of 100 in certain aspects, according to estimates from Manas AI Inc. 3

3

. Researchers use small molecules—biological building blocks about 1 nanometer in size that form the basis of most pharmaceuticals—to determine therapeutic applications by checking their ability to dock to pathogens 3

3

. Startups are also applying the technology to study biomarkers, molecules used to diagnose disease and measure treatment effectiveness 3

3

.

Strategic Timing Ahead of Potential IPO

The acquisition marks Anthropic's third known purchase in the past six months, following task automation startup Vercept Inc. and the developer of Bun, a popular open-source tool for building JavaScript applications 3

3

4

4

. The deal comes as Anthropic eyes a potential IPO as early as October 4

4

. When Anthropic announced in February that it raised $30 billion in a Series G funding round at a $380 billion valuation, it attributed investor interest in part to its strength in enterprise AI and coding 5

5

.

The company's run-rate revenue has reached $14 billion, growing more than tenfold annually for three consecutive years, and the customer base spending over $100,000 a year on Claude has grown sevenfold 2

2

. But that growth is overwhelmingly concentrated in coding, enterprise search, and general productivity, making healthcare and life sciences a vast adjacent market opportunity 2

2

. Venture capital appetite reflects this calculus: Breakout Ventures closed a $114 million fund in March explicitly targeting early-stage biotechs that treat AI and biology as inseparable, while Dimension itself is reportedly raising a $700 million third fund 2

2

.